X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Entresto (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of additional indication of pediatric chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Entresto (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of additional indication of pediatric chronic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
Entresto contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. It inhibits neprilysin via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 receptor via valsartan in pediatric heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Sacubitril and Valsartan drug inhibits neprilysin and blocks angiotensin II type-I receptor, increasing the levels of peptides degraded by neprilysin. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Valentas
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Sacubitril and Valsartan drug inhibits neprilysin and blocks angiotensin II type-I receptor, increasing the levels of peptides degraded by neprilysin. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Sacu V
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Under the agreement, Dr. Reddy’s will be assigned and transferred the Cidmus trademark in India from Novartis. The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Cidmus
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2022
Details:
The Delhi High Court has passed an injunction in favour of Novartis AG against four Indian generic manufacturers, in a patent infringement suit filed by the former for its heart-failure drug marketed as Vymada in India and sold internationally as Entresto.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vymada
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
In Paradise-MI trial, patients on Entresto were 10% less likely than those on ramipril to be hospitalized for heart failure, die of cardiovascular causes or develop symptomatic heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2021
Details:
Sacubitril and Valsartan drug inhibits neprilysin and blocks angiotensin II type-I receptor, increasing the levels of peptides degraded by neprilysin. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Sacubitril/Valsartan-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
Entresto's label expansion is based on efficacy and safety evidence observed in PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with guideline-defined HFpEF.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LCZ696
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd
Deal Size: Undisclosed Upfront Cash: $90.0 million
Deal Type: Agreement March 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
